logo

Protagonist Therapeutics, Inc (PTGX)



Trade PTGX now with
  Date
  Headline
6/17/2020 11:11:20 PM Hepcidin Mimetic PTG-300 Gets U.S. FDA Orphan Drug Designation For The Treatment Of Polycythemia Vera
5/28/2020 6:52:08 AM Protalix BioTherapeutics Announces Submission Of BLA To FDA For Pegunigalsidase Alfa
5/12/2020 12:58:25 AM Protagonist Therapeutics Prices Public Offering Of 7 Mln Shares At $14/Shr
5/11/2020 7:01:09 AM Protagonist Therapeutics Begins 5 Mln Public Offering Of Common Stock
3/10/2020 4:05:08 PM Protagonist Therapeutics Q4 Loss/share $0.63 Vs. Loss $0.57 Year Ago
2/7/2020 7:02:29 AM Protagonist Therapeutics To Present Preclinical Results On PN-943 At The 15th Congress Of ECCO
1/6/2020 7:07:01 AM Protagonist Therapeutics Begins Phase 2 Study Of Novel Hepcidin Mimetic PTG-300 For Hereditary Hemochromatosis
8/7/2019 7:07:26 AM Protagonist Therapeutics Q2 Net Loss $29.2 Mln Vs. Net Loss $8.7 Mln Last Year
5/29/2019 4:31:43 PM Protagonist Therapeutics Appoints Don Kalkofen As CFO
5/8/2019 7:13:07 AM Protagonist Therapeutics Q1 Net Loss $14.1 Mln Vs. Net Loss $7.7 Mln Last Year
3/12/2019 4:04:31 PM Protagonist Therapeutics Q4 Loss/share $0.57 Vs. Loss $0.15 Year Ago
1/9/2019 7:02:22 AM Protagonist Therapeutics Initiates Phase 2 Trial Of Novel Hepcidin Mimetic PTG-300 For Beta Thalassemia